Clinical Study

Posttransplant Allosensitization in Low Immunological Risk Kidney and Kidney-Pancreas Graft Recipients

Table 2

Risk factors for anti-HLA antibodies positivity at 6 months by multivariable* logistic regression analysis.

Odds ratio95% IC value

Risk factors for anti-HLA (+)
 ATG use3.051.49–6.25<0.01
 Acute rejection
  No episodeReference
  Steroid-sensitive1.750.59–5.160.31
  Steroid-insensitive6.472.55–16.42<0.01
Risk factors for anti-HLA class I (+)
 ATG use4.041.89–8.65<0.01
 Acute rejection
  No episodeReference
  Steroid-sensitive1.050.29–3.870.94
  Steroid-insensitive4.451.63–12.09<0.01
Risk factor for anti-HLA class II (+)
 Acute rejection
  No episodeReference
  Steroid-sensitive3.900.99–15.420.05
  Steroid-insensitive5.051.46–17.460.01

Variables included in the model are ATG use, time on dialysis, kidney-pancreas graft, acute rejection type, recipient age, and donor age, ABDR mismatches.
HLA: human leukocyte antigen; IC: confidence interval; ATG: antithymocyte globulin.